c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Huncharek M, Muscat J. Genetic characteristics of prostate cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:681-7; PMID:8547836
   PubMed Web of Science ®Google Scholar
• Gann PH. Risk factors for prostate cancer. Rev Urol 2002; 4:S3-10; PMID:16986064
   PubMedGoogle Scholar
• Bosland MC, Ozten N, Eskra JN, Mahmoud AM. A perspective on prostate carcinogenesis and chemoprevention. Curr Pharmacol Rep 2015; 1:258-65; PMID:26442200; http://dx.doi.org/10.1007/s40495-015-0031-0
   PubMedGoogle Scholar
• Li Y, Ahmad A, Kong D, Bao B, Sarkar FH. Recent progress on nutraceutical research in prostate cancer. Cancer Metastasis Rev 2014; 33:629-40; PMID:24375392; http://dx.doi.org/10.1007/s10555-013-9478-9
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 2011; 130:157-76; PMID:21277893; http://dx.doi.org/10.1016/j.pharmthera.2011.01.010
   PubMed Web of Science ®Google Scholar
• Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 2009; 11:1139-48; PMID:19203212; http://dx.doi.org/10.1089/ars.2009.2440
   PubMed Web of Science ®Google Scholar
• Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med 2012; 12:1244-52; PMID:22834827; http://dx.doi.org/10.2174/156652412803833508
   PubMed Web of Science ®Google Scholar
• Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 1994; 55:1061-9; PMID:8084211; http://dx.doi.org/10.1016/0024-3205(94)00641-5
   PubMed Web of Science ®Google Scholar
• Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003; 278:35501-7; PMID:12816951; http://dx.doi.org/10.1074/jbc.M302967200
   PubMed Web of Science ®Google Scholar
• Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol 2004; 10:3459-63; PMID:15526365; http://dx.doi.org/10.3748/wjg.v10.i23.3459
   PubMed Web of Science ®Google Scholar
• Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 2007; 109:1279-89; PMID:17326044; http://dx.doi.org/10.1002/cncr.22551
   PubMed Web of Science ®Google Scholar
• Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 2007; 30:1529-37; PMID:17487375
   PubMed Web of Science ®Google Scholar
• Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, et al. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 2011; 6:e18490; PMID:21559510; http://dx.doi.org/10.1371/journal.pone.0018490
   PubMed Web of Science ®Google Scholar
• Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer 2009; 124:2709-18; PMID:19219913; http://dx.doi.org/10.1002/ijc.24244
   PubMed Web of Science ®Google Scholar
• Pan HC, Lai DW, Lan KH, Shen CC, Wu SM, Chiu CS, Wang KB, Sheu ML. Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model. Carcinogenesis 2013; 34:2568-79; PMID:23828905; http://dx.doi.org/10.1093/carcin/bgt243
   PubMed Web of Science ®Google Scholar
• Chilampalli S, Zhang X, Fahmy H, Kaushik RS, Zeman D, Hildreth MB, Dwivedi C. Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res 2010; 30:777-83; PMID:20392996
   PubMed Web of Science ®Google Scholar
• Pan J, Zhang Q, Liu Q, Komas SM, Kalyanaraman B, Lubet RA, Wang Y, You M. Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function. Cancer Prev Res (Phila) 2014; 7:1149-59; PMID:25245764; http://dx.doi.org/10.1158/1940-6207.CAPR-14-0091
   PubMed Web of Science ®Google Scholar
• Li W, Wang Q, Su Q, Ma D, An C, Ma L, Liang H. Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. Mol Cells 2014; 37:383-8; PMID:24810210; http://dx.doi.org/10.14348/molcells.2014.0009
   PubMed Web of Science ®Google Scholar
• Ponnurangam S, Mammen JM, Ramalingam S, He Z, Zhang Y, Umar S, Subramaniam D, Anant S. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol Cancer Ther 2012; 11:963-72; PMID:22319203; http://dx.doi.org/10.1158/1535-7163.MCT-11-0999
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen L, He X, Fan L, Yang G, Chen X, Lin X, DU L, Li Z, Ye H, et al. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer 2008; 18:652-9; PMID:17892458; http://dx.doi.org/10.1111/j.1525-1438.2007.01070.x
   PubMed Web of Science ®Google Scholar
• Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb Magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 2008; 14:1248-57; PMID:18281560; http://dx.doi.org/10.1158/1078-0432.CCR-07-1926
   PubMed Web of Science ®Google Scholar
• Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007; 6:2686-95; PMID:17938262; http://dx.doi.org/10.1158/1535-7163.MCT-07-0217
   PubMed Web of Science ®Google Scholar
• Hahm ER, Karlsson AI, Bonner MY, Arbiser JL, Singh SV. Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate 2014; 74:408-20; PMID:24338950; http://dx.doi.org/10.1002/pros.22762
   PubMed Web of Science ®Google Scholar
• Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One 2013; 8:e63563; PMID:23704919; http://dx.doi.org/10.1371/journal.pone.0063563
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chou CJ, Cheng FC, Chen CF. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 655:41-5; PMID:8061832; http://dx.doi.org/10.1016/0378-4347(94)00031-X
   PubMed Web of Science ®Google Scholar
• Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65:11565-71; PMID:16357166; http://dx.doi.org/10.1158/0008-5472.CAN-05-3441
   PubMed Web of Science ®Google Scholar
• Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21:1156-67; PMID:18567993; http://dx.doi.org/10.1038/modpathol.2008.111
   PubMed Web of Science ®Google Scholar
• Sears RC. The life cycle of C-Myc: From synthesis to degradation. Cell Cycle 2004; 3:1133-7; PMID:15467447; http://dx.doi.org/10.4161/cc.3.9.1145
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009; 106:3207-12; PMID:19202062; http://dx.doi.org/10.1073/pnas.0808042106
   PubMed Web of Science ®Google Scholar
• Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta 2015; 1849:506-16; PMID:24704206; http://dx.doi.org/10.1016/j.bbagrm.2014.03.013
   PubMed Web of Science ®Google Scholar
• Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post- transcriptional mechanisms. Oncotarget 2011; 2:669-83; PMID:21941025; http://dx.doi.org/10.18632/oncotarget.327
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell 2012; 149:22-35; PMID:22464321; http://dx.doi.org/10.1016/j.cell.2012.03.003
   PubMed Web of Science ®Google Scholar
• Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010; 1:617-28; PMID:21779461; http://dx.doi.org/10.1177/1947601910379132
   PubMedGoogle Scholar
• Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One 2010; 5:e9427; PMID:20195545; http://dx.doi.org/10.1371/journal.pone.0009427
   PubMedGoogle Scholar
• Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524-31; PMID:9012485
   PubMed Web of Science ®Google Scholar
• Zhang X, Lee C, Ng P-Y, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of c-myc oncoprotein. Prostate 2000; 43:278-85; PMID:10861747; http://dx.doi.org/10.1002/1097-0045(20000601)43:4%3c278::AID-PROS7%3e3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4:223-38; PMID:14522256; http://dx.doi.org/10.1016/S1535-6108(03)00197-1
   PubMed Web of Science ®Google Scholar
• Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-κB activation pathway. Mol Cancer Res 2006; 4:621-33; PMID:16966432; http://dx.doi.org/10.1158/1541-7786.MCR-06-0076
   PubMed Web of Science ®Google Scholar
• Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, et al. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 2009; 277:133-40; PMID:19135778; http://dx.doi.org/10.1016/j.canlet.2008.11.029
   PubMed Web of Science ®Google Scholar
• Yao CJ, Lai GM, Yeh CT, Lai MT, Shih PH, Chao WJ, Whang-Peng J, Chuang SE, Lai TY. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/β-Catenin signaling and apoptosis induction. Evid Based Complement Alternat Med 2013; 2013:146136; PMID:23662112
   PubMed Web of Science ®Google Scholar
• Oswald F, Lovec H, Möröy T, Lipp M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene 1994; 9:2029-36; PMID:8208548
   PubMed Web of Science ®Google Scholar
• Schorl C, Sedivy JM. Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell 2003; 14:823-35; PMID:12631706; http://dx.doi.org/10.1091/mbc.E02-10-0649
   PubMed Web of Science ®Google Scholar
• Sheen JH, Dickson RB. Overexpression of c-Myc alters G1/S arrest following ionizing radiation. Mol Cell Biol 2002; 22:1819-33; PMID:11865060; http://dx.doi.org/10.1128/MCB.22.6.1819-1833.2002
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075
   PubMed Web of Science ®Google Scholar
• Li K, Chen MK, Situ J, Huang WT, Su ZL, He D, Gao X. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery. Chin Med J 2013; 126:82-7; PMID:23286483
   PubMed Web of Science ®Google Scholar
• Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One 2012; 7:e30393; PMID:22272343; http://dx.doi.org/10.1371/journal.pone.0030393
   PubMedGoogle Scholar
• Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004; 23:5594-606; PMID:15184882; http://dx.doi.org/10.1038/sj.onc.1207747
   PubMed Web of Science ®Google Scholar
• Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis 2003; 24:891-7; PMID:12771033; http://dx.doi.org/10.1093/carcin/bgg023
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar